ArticleThrombosis journal2026
A post-marketing surveillance study on the safety and effectiveness of recombinant antithrombin gamma in patients with congenital antithrombin deficiency in Japan.
Article in Thrombosis journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCongenital antithrombin deficiency (CAD) is a serious inherited thrombophilia, classified as a rare disease. According to a study measuring antithrombin (AT) activity in the general Japanese population, approximately one in 650 people (0.15%) have AT deficiency. Deep vein thrombosis of the lower limbs is the most common clinical symptom. Pregnancy further increases the risk of venous thromboembolism in thrombophilia carriers. Recombinant human AT gamma (rhAT-gamma) is marketed for the treatment of thrombophilia due to CAD; however, no clinical trials for Japanese CAD patients have been conducted.
methodsPost-marketing surveillance was conducted at 22 sites in Japan from April 2016 to March 2022 to evaluate the safety and effectiveness of rhAT-gamma under clinical use conditions in CAD patients. Patients who had received rhAT-gamma for thrombophilia due to CAD were enrolled. The observation period for each patient was 12 months after treatment initiation or 28 days after the end of treatment.
resultsDuring the study period, 28 patients were recruited. Of these, 22 patients (1 man, 21 women) comprised the safety and effectiveness population. The reasons for rhAT-gamma use overlapped, being surgery in 13.6% (3/22) of the patients, pregnancy in 86.4% (19/22), and others in 22.7% (5/22). rhAT-gamma was administered at 20–94 IU/kg once daily. In the safety evaluation, adverse events (AEs) and adverse drug reactions were observed in 31.8% (7/22) and 18.2% (4/22) of the patients, respectively. Serious AEs occurred in 9.1% (2/22) of the patients; no AEs resulted in death. In the effectiveness evaluation, rhAT-gamma was judged effective in all patients. AT activity increased in most patients, contributing to safe delivery outcomes in pregnant women. Although the data were limited, D-dimer levels decreased after rhAT-gamma administration.
conclusionsrhAT-gamma was safe and tolerable in Japanese CAD patients, with an increase in AT activity confirmed in most patients. Among pregnant women with a higher risk of thrombosis, no thrombosis was observed before or after delivery, leading to safe childbirth.
trial registrationUniversity Hospital Medical Information Network; study ID, UMIN000050276; date of registration, 8 February 2023 (retrospectively registered).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.